Dynavax Technologies Corporation (DVAX)

NASDAQ
9.250
+0.300(+3.35%)
After Hours
9.240
-0.010(-0.108%)
- Real-time Data
  • Volume:
    2,004,044
  • Bid/Ask:
    9.220/9.250
  • Day's Range:
    8.850 - 9.275

DVAX Overview

Prev. Close
8.95
Day's Range
8.85-9.275
Revenue
118.96M
Open
8.9
52 wk Range
3.59-12.44
EPS
-0.62
Volume
2,004,044
Market Cap
1.06B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,547,564
P/E Ratio
-
Beta
1.22
1-Year Change
26.02%
Shares Outstanding
114,588,212
Next Earnings Date
Aug 11, 2021
What is your sentiment on Dynavax Technologies Corporation?
or
Market is currently closed. Voting is open during market hours.

Dynavax Technologies Corporation News

Dynavax Technologies Corporation Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation Company Profile

Employees
245

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Read More
  • covid-19 vaccine on the way?
    0
    • This is my 2021 play. Great stock
      1
      • to the moon
        3
        • Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine
          0
          • 8.77
            0
            • Looks like will close above 9.5-9.6, bullish. This up momentum is established on fundmental supports, the adjuvent, plus short squeezing. Be patient with the new trial and get paid later.
              0
              • Next tp 12.5. Above 24 if phase 3 goes well.
                0
                • When phase 3 is planned?
                  0
              • BS hype, pump and dump
                2
                • Sell your then
                  0
              • Dynavax Technologies Dynavax Technologies could go up to 15 ... maybe. Watch out for EHang ... the tesla of the skies
                0
                • from 6 to 10.27....62% ...well done
                  0
                  • I pay for a newsletter and this stock was recommended this morning. For a long term buy and hold. Got in @ $9.25 holding til $20
                    0
                    • Sell or hold? How long is the optimism going to last?
                      0
                      • Hope revived.. At one point was thinking of selling with 50% loss, glad didnt.. Famous saying" U only make loss if u sell"
                        2
                        • load up ladies and gents, load up!!
                          0
                          • still going up, nice
                            0
                            • Time to load up.
                              0
                              • Time to load again!
                                0
                                • you are all captains of titanic? this is a junk stock with a lot of speculations based on rumors and false hopes. I jumped off the sinking boat two months ago.
                                  1
                                  • where did you land?
                                    0
                                  • your loss! biggggggg lossss! hows the view from the sidelines? 🤣😂🤣
                                    0
                                • Probability Of Bankruptcy??
                                  2
                                  • Shorty!!!! Go to ******
                                    0
                                • Is Dynavax going to release positive note on Covid vaccine soon?
                                  0
                                  • Is Dynavax going to release positive note on Covid vaccine soon?
                                    0
                                    • 👍🎉 investors.dynavax.com/node/18386/pdf
                                      0
                                      • Whats this? Wont open
                                        0
                                      • https://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=50
                                        0
                                      • Thank you for sharing this doc.   Interesting read
                                        0
                                    • 👍🎉 investors.dynavax.com/node/18386/pdf
                                      0
                                      • why it's up!?!
                                        0
                                        • ROCE
                                          0
                                      • Bill Gates foundation don't give money for go in bankruptcy tovarisch Yuri
                                        1
                                        • mistakes happened, nobody guarantied- all human .  And by my opinion previous DVAX management  paid to analytics, to promote their stock, not first time on my 10 years experience  at trade. Otherwise for such company downside for 120 % , just ridiculous.
                                          0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.